|
Abstract:
|
Network meta-analysis and indirect treatment comparison are playing an increasingly important role in pharmaceutical industry for evidenced-based decision making. There are well-established methods to synthesize evidence from aggregated data (AD) from randomized clinical trial (RCT). Methods have also been proposed to combine the individual patient data (IPD) with AD. With the wide availability of real-world data for clinical research, evidence synthesis across data from randomized and non-randomized studies is another active research area. In this presentation, we will compare methodologies for evidence synthesis from different sources and levels, the key differences between the methodologies in terms of underlying assumptions, strength, and limitation. Tool availability and performance of these methods will also be reported. This is to provide a better understanding of the current landscape of network meta-analysis in evidence synthesizing across different data sources with varying quality, and recommend best practices to address the challenges.
|
